Michael Sabel

Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial

Wolfgang Wick, Michael Platten, Christoph Meisner et al. · The Lancet Oncology · 2012 · 1.1K citations · Full text

Neuro-oncology, Temozolomide Chemotherapy, Malignant Astrocytoma +9

NOA-04 Randomized Phase III Trial of Sequential Radiochemotherapy of Anaplastic Glioma With Procarbazine, Lomustine, and Vincristine or Temozolomide

Wolfgang Wick, Christian Hartmann, Corinna Engel et al. · Journal of Clinical Oncology · 2009 · 804 citations

Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial

Ulrich Herrlinger, Theophilos Tzaridis, Frederic Mack et al. · The Lancet · 2019 · 556 citations · Full text

Hematological Malignancy, Neuro-oncology, Treatment Strategies +13

<i>MGMT</i> Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial

Michael Weller, Ghazaleh Tabatabai, Bärbel Kästner et al. · Clinical Cancer Research · 2015 · 311 citations · Full text

Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups

Michael Weller, Ruthild G. Weber, Edith Willscher et al. · Acta Neuropathologica · 2015 · 307 citations · Full text

Pathology, High-grade Gliomas, Brain Lesion +18